Coagulation Factor III

Coagulation Factor III Informations sur la molécule

Nom anglaisTissue factorNombre de médicaments commercialisés1
Nombre de médicaments cliniques7Alias de la cibleCoagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Phase de R&D la plus avancéeApproved
Nom anglaisTissue factor
Alias de la cibleCoagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques7
Phase de R&D la plus avancéeApproved

Coagulation Factor IIIContexte de la molécule

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor IIIAlias de la molécule

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
AnpocoginAB-201Phase 3 ClinicalDendreon Uk LtdCoronavirus Disease 2019 (COVID-19)
Details
XNW-28012XNW-28012; XNW28012Phase 3 ClinicalShanghai Cigna Biotech Pharmaceutical Co LtdOvarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
MRG-004AMRG004APhase 3 ClinicalShanghai Miracogen IncPancreatic Neoplasms; Solid tumours
Details
XB-002XB-002; ICON-2Phase 1 ClinicalIconic Therapeutics IncBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms
Details
XB-371XB-371; XB371Phase 1 ClinicalCatalent Inc, Exelixis IncNeoplasms; Solid tumours
Details
STRO-004STRO-004Phase 1 ClinicalSutro Biopharma IncCarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
AMT-754ADCE-T02; AMT-754Phase 1 ClinicalMultitude Therapeutics IncSolid tumours
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Tisotumab vedotinTF-011-MMAEApprovedGenmab A/SHuMax-TF, TIVDAKUnited StatesUterine Cervical NeoplasmsSeagen Inc2021-09-20Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques